Clinical Trial Update: Ph 1, Single-Center, Safety, Tolerability & Pharmacokinetic Study of KX2 391 Ointment in Subj. w Actinic Keratosis [Phase 1]

View source ↗

Summary

A Phase 1, single-center study evaluating safety, tolerability, and pharmacokinetics of KX2-391 ointment in patients with actinic keratosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Actinic Keratosis

Drugs mentioned

• KX2-391 ointment (KX2-391)

Snippet

Sponsor: Athenex, Inc. | Conditions: Actinic Keratosis | Phase 1 | Status: COMPLETED